The primary objective of the perioperative study is to evaluate pathological complete response in resectable II-IIIB(N2) KRAS-mutated nonsquamous non-small cell lung cancer participants receiving tislelizumab plus platinum-based doublet chemotherapy.
Able to provide written informed consent (ICF) and able to understand and comply with the study requirements and assessment schedule.
Male or female aged ≥18 years at the time of signing the ICF.
Histologically or cytologically confirmed stage II-IIIB (N2) non-squamous non-small cell lung cancer (NSCLC) (AJCC 8th edition).
With Known KRAS gene mutation.
Previously received any treatment for the current lung cancer, including radiotherapy and all systemic anti-tumor treatments, including chemotherapy, immunotherapy, targeted therapy, or anti-angiogenic therapy.
Presence of locally advanced, unresectable disease, regardless of disease stage or presence of metastases.
Received other approved systemic immunomodulatory agents (including but not limited to interferon, interleukin-2, tumor necrosis factor, thymosin α1, and thymalfasin) within 4 weeks prior to the first dose.
Used any herbal medicine to control cancer within 14 days prior to the first dose of the study drug.
Single group
Tislelizumab
Drugadministered via Intravenous (IV) injection
Cisplatin
Drugadministered via IV infusion
Carboplatin
Drugadministered via IV infusion
Pemetrexed Disodium
Drugadministered via IV infusion
Pathological complete response (pCR) rate
Major pathological response (MPR) rate
Objective Response Rate (ORR)
Event-free survival (EFS)
Overall survival (OS)
Click on the lead sponsor to view all of their trials.
